RNA Therapies

Are you designing and developing RNA-based therapies? Do you need to optimize them and develop efficient delivery systems that target specific tissues and protect their cargo from premature clearance?

This is where Genedata comes in.

Request a Demo

Our Customers

RNA Discovery. Better Candidates.
Assay Analysis. Speed Up. Scale.
Bioprocess Development. Structured. E2E.
MS-Based Analysis. Quality Ensured.
Next-Generation Sequencing. Optimized.
Clinical & Translational Research. Accelerated.

RNA Discovery. Better Candidates.

Capture all data end-to-end relating to design, analysis, and production of a variety of RNA-based therapeutics and support transparent decision-making at each step.
Leverage tools out-of-the-box for DNA and RNA sequence design and in silico engineering.
Register modified nucleosides, terminal modifications (e.g., 5' cap structures), and automatically calculate associated physicochemical properties.
Track diverse delivery systems and their components, e.g., exact lipid composition of associated lipid nanoparticles (LNPs).

Assay Analysis. Speed Up. Scale.

Accelerate testing of nucleic acid-based therapeutic candidates by automating analysis of biological assays – from multiplexed qPCR to cellular functional assays.
Streamline and harmonize analysis to improve data quality and enable cross-assay analysis during target identification and validation, oligo optimization, or formulation screening.
Ensure traceability from raw data to results with automated data loading and vendor-agnostic Ready-to-Run instrument integrations.
Visualize and analyze assay data according to the highest industry standards with scientifically validated built-in normalization methods, fitting algorithms, and data models.

Bioprocess Development. Structured. E2E.

Track and integrate data end-to-end during process development for nucleic acid therapeutics including in vitro transcription.
Facilitate identification and registration of critical quality attributes (CQAs), critical process parameters (CPPs), and critical material attributes (CMAs) during all production steps.
Enforce data integrity in complex formulations using automatic uniqueness validation.
Ensure seamless data and material transfer between departments using an integrated request management system.

MS-Based Analysis. Quality Ensured.

Streamline MS-based analytics of therapeutic oligonucleotides, e.g., intact mass analysis, oligo metabolite IDs, impurity testing, and MS/MS analysis for sequence confirmation.
Automate time-consuming and laborious manual operations during MS-based analyses.
Support deployment in regulated GxP environments through highly flexible custom workflows and built-in compliance features.
Enable systematic optimization of synthetic process parameters by eliminating analytical bottlenecks.

Next-Generation Sequencing. Optimized.

Automate NGS-based workflows used in design, development, and quality control of nucleic acid-based therapeutics.
Enable automated CRISPR-based target engineering, transgene integration assessment, and registration and annotation of proprietary genomes.
Facilitate NGS-based CQA analysis and Multi-Attribute Methodology (MAM) assessment during bioprocess development.
Support all NGS-based biosafety testing in a GMP environment.

Clinical & Translational Research. Accelerated.

Seamlessly integrate, harmonize, and analyze multimodal data in a secure, validation-ready environment.
Facilitate advanced multi-omics analytics to empower discovery of predictive biomarkers and design of the most targeted and safest nucleic acid-based therapeutics.
Track and visualize clinical trial results in real time to support early data-informed decisions and ensure clinical success.
Democratize access to R&D data and data-driven insights across the organization to streamline cross-team collaboration and enhance productivity.